J147
CAS No. 1146963-51-0
J147 ( J147; J 147; J-147 )
Catalog No. M10519 CAS No. 1146963-51-0
J-147 is a broad spectrum neuroprotective phenyl hydrazide compound(EC50=60-115 nM) with significant neurotrophic properties related to the induction of brain-derived neurotrophic factor (BDNF).
Purity : >98%(HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 59 | In Stock |
|
10MG | 85 | In Stock |
|
25MG | 141 | In Stock |
|
50MG | 210 | In Stock |
|
100MG | 312 | In Stock |
|
500MG | 737 | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJ147
-
NoteResearch use only, not for human use.
-
Brief DescriptionJ-147 is a broad spectrum neuroprotective phenyl hydrazide compound(EC50=60-115 nM) with significant neurotrophic properties related to the induction of brain-derived neurotrophic factor (BDNF).
-
DescriptionJ-147 is a broad spectrum neuroprotective phenyl hydrazide compound(EC50=60-115 nM) with significant neurotrophic properties related to the induction of brain-derived neurotrophic factor (BDNF).
-
SynonymsJ147; J 147; J-147
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorBDNF
-
Research AreaNeurological Disease
-
Indication——
Chemical Information
-
CAS Number1146963-51-0
-
Formula Weight350.34
-
Molecular FormulaC18H17F3N2O2
-
Purity>98%(HPLC)
-
SolubilitySoluble in DMSO
-
SMILESO=C(N(C1=CC=C(C)C=C1C)/N=C/C2=CC=CC(OC)=C2)C(F)(F)F
-
Chemical Name2,2,2-Trifluoroacetic acid 1-(2,4-Dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Lapchak PA, et al. J Neurol Neurophysiol. 2013 Aug;4(3). pii: 158.
molnova catalog
related products
-
C-82
C-82 is a specific CBP/β-catenin antagonist. It inhibits the binding between β-catenin and CBP and increases the binding between β-catenin and p300.
-
2-methyl-2,3,4,5-tet...
2-methyl-2,3-dihydro-1,5-benzothiazepin-4(5H)-one is ligand of CBP.
-
FHD-286
FHD-286 is an inhibitor of BRM/BRG1 ATPase and can be used for studies on the treatment of BAF-related disorders such as acute myeloid leukemia.